Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives [Corrigendum]

McCulloch D, Brown C, Iland H. Onco Targets Ther. 2017;10:1585–1601.

On page 1594, Table 3 contained several errors. The correct table is presented below and the notes section has been updated throughout the table accordingly.

Table 3.

Commonly employed current treatment regimens in APL, stratified by risk category

Protocol	Induction	Consolidation	Maintenance
Low-intermediate risk
APL040639	ATRA 45 mg/m2/d PO + ATO 0.15 mg/kg/d IV until CR (max 60 days)	ATRA 45 mg/m2/d PO for 14 days then rest for 14 days ×7 cycles + ATO 0.15 mg/kg/d IV for 5 days per week for 4 weeks then rest for 4 weeks ×4 cycles	Nil
LPA200537	ATRA 45 mg/m2/d POa until CR + Idarubicin 12 mg/m2/d d2, 4, 6, 8b	1. ATRA 45 mg/m2/d PO d1–15 + Idarubicin 5low/7int mg/m2/d d1–4 2. ATRA 45 mg/m2/d PO d1–15 + MTZ 10 mg/m2/d d1–3 3. ATRA 45 mg/m2/d PO d1–15 + Idarubicin 12 mg/m2/d d1low or d1–2int	ATRA 45 mg/m2/day PO d1–15 every 3 months MTX 15 mg/m2/wk IM d15–90 6-MP 50 mg/m2/d PO d15–90 for 2 years
High risk
APML438	ATRA 45 mg/m2/day PO d1–36 ATO 0.15 mg/kg/day IV d9–36 Idarubicin 6–12 mg/m2 d2, 4, 6, 8c,d	1. ATRA 45 mg/m2/d PO days 1–28 + ATO 0.15 mg/kg/d IV d1–28 2. ATRA 45 mg/m2/d PO d1–7, 15–21 and 29–35 + ATO 0.15 mg/kg/d IV for 5 days per week for 5 weeks	ATRA 45 mg/m2/day PO d1–14 every 90 days MTX 5–15 mg/m2/wk PO d15–90 6-MP 50–90 mg/m2/d PO d15–90 ×8 cycles
Study C971036	ATRA 45 mg/m2/d PO until CR (max 90 days) + Cytarabine 200 mg/m2 IV d3–9 + DNR 50 mg/m2 IV d3–6	1. ATO 0.15 mg/kg/d IV for 5 days per week for 5 weeks ×2 cycles 2. ATRA 45 mg/m2/d PO days 1–7 + DNR 50 mg/m2 IV d1–3 ×2 cycles	ATRA 45 mg/m2/d PO days 1–7 repeated on alternate weeks MTX 20 mg/m2/wk PO 6-MP 60 mg/m2/d PO for 1 year
APL200096	ATRA 45 mg/m2/d PO until CR + Cytarabine 200 mg/m2 d1–7 + DNR 60 mg/m2 d1–3	1. DNR 60 mg/m2/d d1–3 + Cytarabine 200 mg/m2/d d1–7 2. DNR 45 mg/m2/d d1–3 + Cytarabine 2 g/m2/12h d1–5 (<50 years) or Cytarabine 1.5 g/m2/12h d1–5 (50–60 years) or Cytarabine 1.0 g/m2/12h d1–4 (>60 years) + 5 doses of MTX 15 mg/Cytarabine 50 mg/Depomedrol given IT	ATRA 45 mg/m2/day PO d1–15 every 90 days MTX 15 mg/m2/wk PO d15–90 6-MP 50 mg/m2/d PO d15–90 for 2 years
LPA200537	ATRA 45 mg/m2/d POa until CR + Idarubicin 12 mg/m2/d d2, 4, 6, 8b	1. ATRA 45 mg/m2/d PO d1–15 + Idarubicin 5 mg/m2/d d1–4 + Cytarabine 1 g/m2/d d1–4e 2. ATRA 45 mg/m2/d PO d1–15 + MTZ 10 mg/m2/d d1–5 3. ATRA 45 mg/m2/d PO d1–15 + Idarubicin 12 mg/m2/d d1 + Cytarabine 150 mg/m2/8h d1–4e	ATRA 45 mg/m2/day PO d1–15 every 3 months MTX 15 mg/m2/wk IM d15–90 6-MP 50 mg/m2/d PO d15–90 for 2 years

Notes:

^aATRA 25 mg/m²/d if <20 years.

^bIf >70 years Idarubicin 12 mg/m² d8 omitted.

^cPrednisolone 1 mg/kg/day PO on d1–10 or until WCC <1×10⁹/L.

^dAge adjusted idarubicin; 1–60 years, 12 mg/m²; 61–70 years, 9 mg/m²; >70 years, 6 mg/m².

^eIf >60 years no Cytarabine given in consolidation and Idarubicin dose as per intermediate risk patients described in LPA2005 low-int risk protocol.

Abbreviations: Low, low risk patients; Int, intermediate risk patients; MTX, Methotrexate; 6-MP, Mercaptopurine; DNR, Daunorubicin; MTZ, Mitoxantrone; IT, intrathecal; IM, intramuscular; IV, intravenous; PO, per os (orally).